These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Treatment of the diffuse and focal proliferative forms of lupus nephropathy with intravenous cyclophosphamide. Intravenous cyclophosphamide in systemic lupus erythematosus].
    Author: Vigil A, Gallar P, Oliet A, Ortega O, Bajo MA.
    Journal: Rev Clin Esp; 1995 Aug; 195(8):524-9. PubMed ID: 7569197.
    Abstract:
    The objective is to evaluate the therapeutic effect and toxicity of IV Cyclophosphamide on the evolution of diffuse and focal proliferative forms of lupus nephritis. It's a prospective, descriptive and non-controlled study. We treated 12 patients (M/F = 1:11, aged 30.07 +/- 14.15) diagnosed by renal biopsy with diffuse proliferative (n = 10) and focal (n = 2) lupus nephritis. All patients received IV Cyclophosphamide. A dose of 1 g/sg.m of body surface area was administered monthly for the first three months and each three months until two years. The follow-up was 34 +/- 24.83 months (range 6-67). Seven patients completed two years of treatment with Cyclophosphamide with a further follow-up of 18.71 +/- 12.36 months (range 6-67). Renal function either improved or remained unchanged. Proteinuria, hematuria and immunologic markers decreased or normalized at three years. The patients who finished the period of two years with CFIV remained stable. There were neither infections nor hemorrhagic cystitis. We conclude that with the scheme of CFIV used by us good therapeutics effects will be obtained with minimum secondary toxicity in a follow-up of three to five years.
    [Abstract] [Full Text] [Related] [New Search]